![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Real-World Health Care Resource Utilization and Quality of Life With Glecaprevir/Pibrentasvir Treatment:
A Pooled Analysis From Post-Marketing Observational Studies
|
|
|
Reported by Jules Levin
AASLD/EASL HCV Special Conference, February 1-2, 2019, Miami, Florida, United States
Alessio Aghemo1, Stefan Bourgeois2, Michael Gschwantler3, Yuri Sanchez Gonzalez4, Lois Larsen4, Mark Bondin4, Rawi Hazzan5, Lorenzo Magenta6, Tarik Asselah7
1Humanitas University and Research Hospital, Rozzano, Italy; 2Department of Gastroenterology and Hepatology, ZNA Antwerp, Antwerp, Belgium; 3Department of Internal Medicine IV, Wilhelminenspital, and Sigmund Freud University, Vienna, Austria; 4AbbVie Inc., North Chicago, Illinois, United States; 5Emek Medical Center, Afula, Israel; 6Epatocentro Ticino, Lugano, Switzerland; 7Hopital Beaujon & INSERM UMR 1149, Clichy, France
![0204191](../images/042019/020419-6/0204191.gif)
![0204192](../images/042019/020419-6/0204192.gif)
![0204193](../images/042019/020419-6/0204193.gif)
![0204194](../images/042019/020419-6/0204194.gif)
![0204195](../images/042019/020419-6/0204195.gif)
![0204196](../images/042019/020419-6/0204196.gif)
![0204197](../images/042019/020419-6/0204197.gif)
![0204198](../images/042019/020419-6/0204198.gif)
![0204199](../images/042019/020419-6/0204199.gif)
![02041910](../images/042019/020419-6/02041910.gif)
![02041911](../images/042019/020419-6/02041911.gif)
![02041912](../images/042019/020419-6/02041912.gif)
![02041913](../images/042019/020419-6/02041913.gif)
![02041914](../images/042019/020419-6/02041914.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|